Author

V. Quaranta

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 5 Pharmacology & Toxicology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 5 Organism:mouse· 4 Research Focus:cell type annotation· 3 Research Focus:drug response / drug discovery· 3 Assay:proteomics· 3 Assay:bulk RNA-seq· 2 Research Focus:cancer & tumor microenvironment· 2 Research Focus:differential expression· 2

Frequent Co-Authors

D. R. Tyson· 3 shared S. M. Groves· 3 shared C. F. Lopez· 2 shared L. A. Harris· 2 shared A. L. R. Lubbock· 1 shared A. Mielgo· 1 shared A. Oleskie· 1 shared A. Richmond· 1 shared

Activity by Year

2017-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 13 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

D. R. Tyson

Mutual co-authors in cluster

Author profile →

7 papers

Recent·Most cited

Purinergic Ca2+ signaling as a novel mechanism of drug tolerance in BRAF mutant melanoma

P. E. Stauffer, J. Brinkley, D. A. Jacobson, V. Quaranta, D. R. Tyson

This study identifies purinergic Ca2+ signaling via P2X7 receptors as a mechanism enabling drug tolerance in BRAF-mutant melanoma, with implications for overcoming treatment resistance.

bioRxiv · Nov 3, 2023Cancer Biology

CXCR2 expression during melanoma tumorigenesis controls transcriptional programs that facilitate tumor growth

J. Yang, K. Bergdorf, C. Yan, W. Luo, S.-C. Chen, D. Ayers, Q. Liu, X. Liu, M. R. Boothby, S. M. Groves, A. Oleskie, X. Zhang, D. Maeda, J. Zebala, V. Quaranta, A. Richmond

This study shows that CXCR2 expression in melanoma progenitor cells drives tumor growth by altering transcriptional programs and immune responses.

bioRxiv · Feb 22, 2023 · PreprintCancer Biology

Involvement of epithelial-mesenchymal transition genes in small cell lung cancer phenotypic plasticity

S. M. Groves, N. Panchy, D. R. Tyson, L. A. Harris, V. Quaranta, T. Hong

This study examines the relationship between epithelial-mesenchymal transition (EMT) and SCLC subtype plasticity using transcriptome data from mouse models and human samples.

bioRxiv · Sep 9, 2022Cancer Biology

Thunor: Visualization and Analysis of High-Throughput Dose-response Datasets

A. L. R. Lubbock, L. A. Harris, V. Quaranta, D. R. Tyson, C. F. Lopez

Thunor is an open-source platform for managing, analyzing, and visualizing dose-response datasets, providing interactive tools for drug response studies.

bioRxiv · Feb 6, 2021Pharmacology & Toxicology

ASCL1 represses a latent osteogenic program in small cell lung cancer in multiple cells of origin

R. R. Olsen, D. W. Kastner, A. S. Ireland, S. M. Groves, K. Pozo, C. P. Whitney, M. R. Guthrie, S. J. Wait, D. Soltero, B. L. Witt, V. Quaranta, J. E. Johnson, T. G. Oliver

This study shows ASCL1 represses a latent osteogenic program in SCLC, promoting tumor initiation and preventing differentiation into bone tumors.

bioRxiv · Nov 11, 2020Cancer Biology

A Consensus Framework Unifies Multi-Drug Synergy Metrics

D. J. Wooten, C. T. Meyer, V. Quaranta, C. F. Lopez

This paper presents a consensus framework to unify multi-drug synergy metrics by identifying biases in existing methods and proposing a mass-action based formalism for accurate synergy measurement.

bioRxiv · Jun 27, 2019 · PreprintPharmacology & Toxicology

Macrophage-derived granulin drives resistance to immune checkpoint inhibition in metastatic pancreatic cancer

V. Quaranta, C. Rainer, S. R. Nielsen, M. Raymant, M. S. Ahmed, D. Engle, A. Taylor, T. Murray, F. Campbell, D. Palmer, D. Tuveson, A. Mielgo, M. Schmid

This study shows that macrophage-derived granulin promotes resistance to immune checkpoint inhibitors in metastatic pancreatic cancer by excluding CD8+ T cells, and blocking granulin improves anti-tumor immunity.

bioRxiv · Dec 15, 2017Cancer Biology